

# Think zinc: transient nutritional deficiency related to novel maternal SLC30A2 mutation potentially precipitated by antenatal proton pump inhibitor exposure

Emma Porter<sup>1</sup>, Oonagh Molloy<sup>1</sup>, Michelle Murphy<sup>1</sup>, and Cathal O'Connor<sup>1</sup>

<sup>1</sup>South Infirmary Victoria University Hospital

January 11, 2023

## Abstract

We present a case of a second-born breastfed infant presenting with zinc deficiency whose mother was found to have a novel heterozygous mutation in SLC30A2. A previous baby did not have manifestations of zinc deficiency but the mother had taken a proton pump inhibitor during the second pregnancy.

DR EMMA PORTER (ORCID 0000-0002-5532-5799)

DR OONAGH MOLLOY (ORCID 0000-0002-2964-8914)

PROF MICHELLE MURPHY (ORCID 0000-0003-2431-076X)

DR CATHAL O'CONNOR (ORCID 0000-0001-7084-5293)

**Think zinc: transient nutritional deficiency related to novel maternal *SLC30A2* mutation potentially precipitated by antenatal proton pump inhibitor exposure**

Emma Porter MD, <sup>1</sup> Oonagh Molloy MD, <sup>1</sup> Michelle Murphy MD, <sup>1, 2</sup> Cathal O'Connor MD <sup>1, 2, 3</sup>

1 Department of Dermatology, South Infirmary Victoria University Hospital, Cork, Ireland

2 Department of Medicine, University College Cork, Ireland

3 INFANT Research Centre, University College Cork, Cork, Ireland

Corresponding author:

Cathal O'Connor, [cathal.oconnor@ucc.ie](mailto:cathal.oconnor@ucc.ie)

Keywords: zinc deficiency, nutritional/metabolic dermatoses, acrodermatitis

Word count: 563

Figure count: 2

Reference count: 6

Conflict of interest statement: The authors declare no conflicts of interest.

Consent statement: The patient's mother has provided consent for publication

**Abstract**

Acquired zinc deficiency is rare, particularly in breastfed infants. We present a case of a second-born breastfed infant presenting with zinc deficiency whose mother was found to have a novel heterozygous mutation in *SLC30A2*. A previous baby did not have manifestations of zinc deficiency but the mother had taken a proton pump inhibitor (PPI) during the second pregnancy. Though little is known regarding the effect of PPI on transplacental or transmammary zinc transmission, antenatal PPI exposure is a plausible contributor to transient infantile zinc deficiency.

## Case Report

A 5-month-old male infant presented with a 3-month history of a progressively worsening scaly eruption associated with recurrent infections, increasing lethargy, poor feeding, and hoarse cry. He had been treated for suspected impetigo with multiple oral antibiotics (amoxicillin, flucloxacillin, and co-trimoxazole). He was born at term, was exclusively breastfed, and had no family history of skin disease. A dramatic periorificial, diaper-area, and acral dermatitis was noted (Fig 1) with loss of occipital hair and thinning of eyelashes. Serum alkaline phosphatase was 41U/L (normal range 82-383U/L) and zinc levels were undetectable at  $<3\mu\text{mol/L}$  (normal range  $10\text{--}25\mu\text{mol/L}$ ). Maternal breastmilk zinc levels were low ( $3.15\mu\text{mol/L}$ , control mean  $12.7\mu\text{mol/L}$ ), and maternal serum zinc was normal. A rapid improvement was noted within days of starting  $3\text{mg/kg/day}$  zinc sulfate supplementation (Fig 2). Zinc supplementation was stopped after 3 months, with normal follow-up zinc levels on cessation, following weaning.

Maternal genetic testing for pathogenic variants in *SLC30A2*, a zinc transporter in mammary tissue, detected a variant c.927G>C, resulting in the substitution of tryptophan for cysteine at amino acid position 309. This variant has an allele frequency of  $<0.01\%$  and *in silico* tools predict that it is pathogenic. The infant's mother had been prescribed omeprazole 20mg once daily from 30 weeks' gestation to birth to treat gastroesophageal reflux (GER). In her previous pregnancy there was no proton pump inhibitor (PPI) ingestion, and no manifestation of zinc deficiency in the older sibling, who had also been exclusively breastfed.

Infantile zinc deficiency is a rare condition presenting within the first six months with periorificial and acral polymorphic and/or erosive crusted plaques. While acrodermatitis enteropathica involves recessive loss-of-function pathogenic variants in *SLC39A4*, acquired transient infantile zinc deficiency (TIZD) can be due to prematurity, low breastmilk zinc levels or malnutrition, or malabsorptive processes such as cystic fibrosis.

<sup>1</sup> It is usually rare in breastfed infants due to enhanced bioavailability of zinc.<sup>2</sup> *SLC30A2* encodes zinc transporter ZnT2, which is responsible for zinc secretion from vesicles in lactating epithelial mammary gland cells.<sup>3</sup> Homodimer formation between the mutant and wild type causes dysfunction and zinc sequestration in lysosomes of mammary tissue, leading to lower levels in breastmilk.<sup>3</sup> The mutation in this case has never been previously reported to cause TIZD.<sup>4</sup> PPI are known to decrease intestinal zinc absorption by increasing intra-luminal pH,<sup>5</sup> as are other medications such as phytates, penicillamine, diuretics, and sodium valproate.<sup>1</sup> However little is known regarding the effect of these drugs on transplacental or transmammary zinc transmission. Infants may be at increased risk for zinc deficiency and related complications due to increased requirements for zinc in growth and development.<sup>5</sup>

In this case, the affected infant's older sibling had no similar presentation during prolonged exclusive breastfeeding, and the mother had only taken omeprazole for the third trimester of this pregnancy, the critical phase of transplacental zinc transfer *in utero*.<sup>6</sup> We hypothesise that antenatal PPI ingestion, in the context of a maternal *SLC30A2* mutation, reduced zinc levels below a threshold that resulted in manifestations of TIZD in this infant. The TIZD in this case also raises concerns about potential nutritional complications of PPI use in infants with physiologic GER.<sup>5</sup>

To our knowledge, this is the first report of this *SLC30A2* mutation associated with TIZD in a breastfed infant, which may have been exacerbated by maternal PPI use during pregnancy, potentially due to diminished transplacental and/or transmammary zinc transmission.

## References

1. Corbo MD, Lam J. Zinc deficiency and its management in the pediatric population: a litera-

- ture review and proposed etiologic classification. *J Am Acad Dermatol*. 2013;69(4):616-624.e1. doi:10.1016/j.jaad.2013.04.028
2. Krebs NF. Zinc transfer to the breastfed infant. *J Mammary Gland Biol Neoplasia*. 1999;4(3):259-268 <https://doi.org/10.1023/A:1018797829351>
3. Tang T, Lam JM. Unique presentation of transient zinc deficiency from low maternal breast milk zinc levels. *Pediatr Dermatol* . 2018;35(2):255-256. doi:10.1111/pde.13349
4. Liew HM, Tan CW, Ho CK, Chee JN, Koh MJ. Transient Neonatal Zinc Deficiency Caused by a Novel Mutation in the SLC30A2 Gene. *Pediatr Dermatol* . 2017;34(2):e104-e105. doi:10.1111/pde.13065
5. Farrell CP, Morgan M, Rudolph DS, et al. Proton Pump Inhibitors Interfere With Zinc Absorption and Zinc Body Stores. *Gastroenterology Res* . 2011;4(6):243-251. doi:10.4021/gr379w
6. Terrin G, Berni Canani R, Di Chiara M, et al. Zinc in Early Life: A Key Element in the Fetus and Preterm Neonate. *Nutrients*. 2015;7(12):10427-10446. doi:10.3390/nu7125542

## Figure Legends

Figure 1. Extensive scaly dermatitis affecting (clockwise from top left) buttocks (a), medial foot (b), and perioral and perinasal skin (c).

Figure 2. Almost complete resolution of dermatitis within 2 weeks of initiation of zinc supplementation.









